This website uses cookies. For more information please contact us or consult our privacy policy.
Your binder contains too many pages, the maximum is 40.
We are unable to add this page to your binder, please try again later.
This page has been added to your binder.
- Home
- News and Insights
- Insights
- HRSA Issues Final 340B Orphan Drug Exclusion Rule Imposing New Obligations on Covered Entities and Creating New Risks for Manufacturers
HRSA Issues Final 340B Orphan Drug Exclusion Rule Imposing New Obligations on Covered Entities and Creating New Risks for Manufacturers
July 26, 2013, Covington E-Alert
Covington Advises Meda on Acquisition of Jazz Pharmaceuticals’ Women’s Health Products
Press Release
September 6, 2012
LONDON, 06 September, 2012 — Covington & Burling LLP acted as legal advisers to Meda in an agreement with Jazz Pharmaceuticals to acquire a portfolio of six pharmaceutical products for women for $95 million in cash. The largest and most important product in the portfolio is Elestrin, a patented product with sales of almost 100 MSEK, that doctors prescribe for ...